KLF5 and neoplasm: Sixty FDA-approved anti-tumor drugs and small molecule compounds were used to conduct drug screening assays, and the results showed that compared with monotherapy, the KLF5 inhibitor ML264 significantly increased oxaliplatin sensitivity in oxaliplatin-resistant PDOs (Fig. S3A).